Company: BDRX
Filing Date: 2025-04-29
Form Type: POS AM
Source: 0001214659-25-006581
Chunk: 8

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-29
Form: POS AM
Chunk 8
---
 minimum 500,000 publicly held shares requirement
pursuant to Rule 5550(a)(4), on March 27, 2023 we effected a ratio change in the number of Ordinary Shares represented by our American
depositary shares, or Depositary Shares, from 25 Ordinary Shares per Depositary Share to five Ordinary Shares per Depositary Share.

On June 14, 2023, we held
our annual general meeting of shareholders, or June AGM, and our shareholders passed resolutions, among other procedural items, to approve
the allotment of, and disapplication of pre-emption rights in respect of, up to 7.0 billion Ordinary Shares, or Shareholder Approval.
On June 14, 2023, we also held a general meeting of shareholders, or June GM, and our shareholders passed resolutions to (x)(i) re-designate
our deferred shares into A Deferred Shares, or the Re-Designation, and (ii) subdivide our Ordinary Shares of £0.02 nominal value
each into one ordinary share of £0.001 nominal value and 19 B Deferred Shares of £0.001 nominal value each, each the Subdivision,
which became effective on June 15, 2023 and (y) adopt new articles of association, which make consequential amendments to the existing
articles of association of the Company to reflect the Re-Designation and the Subdivision, together with certain other changes to reflect
that the Ordinary Shares are no longer admitted to trading on AIM.

On July 5, 2023, and in an
effort to bring our Depositary Share price into compliance with NASDAQ’s minimum bid price per share requirement, we effected a
ratio change in the number of Ordinary Shares represented by our Depositary Shares from five Ordinary Shares per Depositary Share to 400
Ordinary Shares per Depositary Share. No fractional Depositary Shares were issued.

On October 4, 2024, and in
an effort to bring our Depositary Share price into compliance with NASDAQ’s minimum bid price per share requirement, we effected
a ratio change in the number of Ordinary Shares represented by our Depositary Shares from 400 Ordinary Shares per Depositary Share to
10,000 Ordinary Shares per Depositary Share. No fractional Depositary Shares were issued.

On November 22, 2024, we held
a general meeting of shareholders, or November GM, and our shareholders passed resolutions to (i) subdivide our Ordinary Shares of £